Correction to: J Exp Clin Cancer Res 39, 82 (2020)
https://doi.org/10.1186/s13046-020-01581-3
Anzeige
Following publication of the original article [1], the authors identified some minor errors in Fig. 4, specifically:
In Fig. 4c, left panel, the original figure presented a misused result of the analysis of Annexin V/7-AAD assay.
Fig. 4
Sur-X promoted necroptosis in colorectal cancer cells. a Cell morphology as determined by Giemsa staining. After treated by 10 μM Sur-X or Con, HCT116 cells were stained with Giemsa and those treated by adriamycin (10 μM for 12 h) was used as a positive control of apoptosis. Scale bar, 50 μm. Three independent experiments were performed. b The real-time detection of RFU (cell membrane damage, necrosis) in HCT116 cells over 6 h with indicated concentrations of Sur-X. NT, no treatment. Three independent experiments were performed. c HCT116 (top) and RKO (bottom) cells were treated by 10 μM Sur-X for 1, 3 and 6 h, or Con for 6 h, and analyzed by Annexin V/7-AAD assay (left panel). Quantification of 7-AAD positive cells, mean and SD of three independent experiments are shown (right panel). d HCT116 and RKO cells were treated by 10 μM Sur-X (0.5, 1, 3 and 6 h) or Con (6 h), the expressions of necroptosis-related proteins were detected by Western blot analysis. GAPDH was used as a loading control. NT, no treatment. Three independent experiments were performed. e-f Effect of Nec-1 s-pretreatment on Sur-X-induced necroptosis in HCT116 (top) and RKO (bottom) assessed by Annexin V/7-AAD assay (e). Quantification of Annexin V positive cells and quantification of 7-AAD positive cells in HCT116 (top) and RKO (bottom), mean and SD of three independent experiments are shown. NT, no treatment; Nec-1 s, cells were treated only by Nec-1 s; Sur-X, cells were treated by Sur-X (10 μM) for 6 h; Nec-1 s + Sur-X, cells were pretreated by Nec-1 s (50 μM) for 12 h and treated by Sur-X in combination with Nec-1 s for another 6 h (f). g Kinetic detection of apoptosis (RLU, phosphatidylserine and Annexin V binding) and necroptosis (RFU, membrane integrity) in HCT116 cells treated by 10 μM Sur-X was conducted simultaneously over 6 h. Three independent experiments were performed. **, p < 0.01; ***, p < 0.001; ****, p < 0.0001; ns, not significant
×
The corrected figure is given here. The corrections do not have any effect on the final conclusions of the paper. The original article has been corrected.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.
Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.
Ein höheres Alter bei der Diagnose eines Endometriumkarzinoms ist mit aggressiveren Tumorcharakteristika assoziiert, scheint aber auch unabhängig von bekannten Risikofaktoren die Prognose der Erkrankung zu verschlimmern.
In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.
Update Onkologie
Bestellen Sie unseren Fach-Newsletterund bleiben Sie gut informiert.
